Stocktoria

XBiotech Inc. XBIT

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2015-04-15 · LEI

XBiotech Inc. (XBIT) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It pays a dividend (safety: no dividend).

Chart by TradingView
61/100
Stocktoria Quality Score · grade B
3/9
Piotroski F — financial health
14.89
Altman Z″ — distress risk · safe
22.9%
Dividend yield 5y avg · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
1 2 2 3 3 4 3 3 1 3 2016201720182019202020212022202320242025
Altman Z″
-3.61 10.82 -3.82 19.69 13.71 14.89 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$2.46 as of 2026-08-01 · -22.2% 1y
$2.23$3.1652-wk
Market cap USD$72M
Dividend yield 5y avg22.9%
Net margin 5y avg-457.6%
Return on equity 5y avg-17%
Beta0.84
Employees87
Revenue trend · last 6y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 27%
Return on equitystronger than 36%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 3/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.793
Retained earnings / assets-0.909
EBIT / assets-0.371
Equity / liabilities14.421

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
XBITXBiotech Inc.3/914.89
JNJJOHNSON & JOHNSON4/922.9+6%
LLYELI LILLY & Co7/955.1+44.7%
MRKMerck & Co., Inc.4/917.4+1.3%
PFEPFIZER INC4/917.8-1.6%
ABBVAbbVie Inc.7/9-0.34105.9+8.6%
BMYBRISTOL MYERS SQUIBB CO7/916.7-0.2%

All Manufacturing companies →

About XBiotech Inc.

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

FAQ

Is XBIT financially healthy?

XBiotech Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does XBIT pay a dividend, and is it safe?

Yes. XBiotech Inc. pays a dividend with a None payout ratio, rated “no dividend” for safety.

How profitable is XBIT?

In FY2025, XBiotech Inc. had a return on equity of -32.4%.

Is XBIT a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on XBiotech Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.